[HTML][HTML] Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia: a randomized, double-blind, phase 3 trial
T Akizawa, M Nangaku, T Yonekawa… - Clinical journal of the …, 2020 - journals.lww.com
Results Of 332 participants screened, 271 participants were randomized (safety evaluation:
271 participants; efficacy evaluation: 267 intent-to-treat population). The mean hemoglobin …
271 participants; efficacy evaluation: 267 intent-to-treat population). The mean hemoglobin …
Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis
AM Meadowcroft, B Cizman, L Holdstock… - Clinical kidney …, 2019 - academic.oup.com
Background This study evaluated the hemoglobin dose response, other efficacy measures
and safety of daprodustat, an orally administered, hypoxia-inducible factor prolyl …
and safety of daprodustat, an orally administered, hypoxia-inducible factor prolyl …
[HTML][HTML] Daprodustat for the treatment of anemia in patients undergoing dialysis
AK Singh, K Carroll, V Perkovic… - … England Journal of …, 2021 - Mass Medical Soc
Background Among patients with chronic kidney disease (CKD), the use of recombinant
human erythropoietin and its derivatives for the treatment of anemia has been linked to a …
human erythropoietin and its derivatives for the treatment of anemia has been linked to a …
Efficacy and safety of daprodustat for treatment of anemia of chronic kidney disease in incident dialysis patients: a randomized clinical trial
AK Singh, B Cizman, K Carroll… - JAMA internal …, 2022 - jamanetwork.com
Importance Daprodustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, is being
evaluated as an oral alternative to conventional erythropoiesis-stimulating agent (ESA) …
evaluated as an oral alternative to conventional erythropoiesis-stimulating agent (ESA) …
Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non …
NW Levin, S Fishbane, FV Cañedo, S Zeig, GM Nassar… - The Lancet, 2007 - thelancet.com
Background Conventional treatment with epoetin to manage anaemia in chronic kidney
disease needs frequent administrations, changes of dose, and close monitoring of …
disease needs frequent administrations, changes of dose, and close monitoring of …
Efficacy and safety of molidustat for anemia in ESA-naive nondialysis patients: a randomized, phase 3 trial
H Yamamoto, K Nobori, Y Matsuda, Y Hayashi… - American journal of …, 2021 - karger.com
Introduction: Molidustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that
predominantly induces renal production of erythropoietin (EPO). Molidustat was evaluated …
predominantly induces renal production of erythropoietin (EPO). Molidustat was evaluated …
Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated …
M Klinger, M Arias, V Vargemezis, A Besarab… - American Journal of …, 2007 - Elsevier
BACKGROUND: CERA (methoxy polyethylene glycol-epoetin beta), a continuous
erythropoietin receptor activator, was developed to provide stable control of hemoglobin …
erythropoietin receptor activator, was developed to provide stable control of hemoglobin …